Literature DB >> 18046528

Replacement of valved right ventricular to pulmonary artery conduits: an observational study with focus on right ventricular geometry.

Tsvetomir Loukanov1, Christian Sebening, Wolfgang Springer, Markus Khalil, Herbert E Ulmer, Siegfried Hagl, Matthias Karck, Matthias Gorenflo.   

Abstract

OBJECTIVE: Timing of the operation for exchange of right ventricular (RV) to pulmonary artery (PA) conduits is a matter of considerable debate. We aimed to study the course of right ventricular dimension in patients undergoing conduit exchange. PATIENTS AND METHODS: We retrospectively studied all patients who underwent implantation and or replacement of RV/PA conduits during the time period between 1990 and 2005. Clinical and echocardiographic data were recorded as obtained at follow-up visits.
RESULTS: A total of 229 (144 boys and 85 girls) underwent surgery for implantation and or replacement of RV/PA conduits during the study period. Patients were assigned to three age groups including 37 infants, 125 children aged 1-10 years and 67 patients more than 10 years of age. 185 pulmonary (81%) and 44 aortic homografts (19%) were implanted. Fifty-eight of these 185 patients (25%) required exchange of conduits after a median time of 6.4 (8 months-12 years) (median (range)). The follow-up was 7.55 (0.1-17) years. The survival of the patients after homograft change was 98%. Freedom from failure for aortic and pulmonary homografts at an interval of 10 years for all patients was 38.5% for aortic and 56.2% for pulmonary homografts (P = 0.018; Mann-Whitney). Age at conduit exchange (coefficient: -4.917; P < 0.001) and right ventricular end-diastolic dimension (RVDD) before conduit exchange (coefficient: 8.255; P < 0.001) were related to RVDD as measured by M-mode echocardiography at follow-up ("best subset" regression analysis; R squared = 0.746). RVDD decreased in 48/58 patients, remained unchanged in 8/58 and increased in 2/59 patients at follow-up. An increased RVDD was positively correlated to the duration of artificial ventilation after the operation for conduit exchange (R = 0.56; P < 0.001).
CONCLUSIONS: Reoperation for exchange of degenerated conduits should be performed early to prevent the development of irreversible structural myocardial changes and persistence of right ventricular dilatation.

Entities:  

Mesh:

Year:  2007        PMID: 18046528     DOI: 10.1007/s00392-007-0599-4

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  21 in total

1.  Are pulmonary homografts which were subjected to pulmonary hypertension more appropriate for aortic valve replacement than normal pulmonary homografts? A long-term multicentric echography study.

Authors:  R Jashari; B Van Hoeck; M Gaudino; W Daenen; T Van Geldorp; P Kalmar; Y Goffin
Journal:  Eur J Cardiothorac Surg       Date:  2000-02       Impact factor: 4.191

2.  Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits.

Authors:  Joseph A Dearani; Gordon K Danielson; Francisco J Puga; Hartzell V Schaff; Carole W Warnes; David J Driscoll; Cathy D Schleck; Duane M Ilstrup
Journal:  Ann Thorac Surg       Date:  2003-02       Impact factor: 4.330

Review 3.  Conduit selection for right ventricular outflow tract reconstruction: contemporary options and outcomes.

Authors:  Joseph M Forbess
Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu       Date:  2004

4.  Correction of pulmonary atresia with a homograft aortic valve.

Authors:  D N Ross; J Somerville
Journal:  Lancet       Date:  1966-12-31       Impact factor: 79.321

5.  Right ventricular outflow tract reconstruction with an allograft conduit.

Authors:  C G Gerestein; J J Takkenberg; F B Oei; A H Cromme-Dijkhuis; S E Spitaels; L A van Herwerden; E W Steyerberg; A J Bogers
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

6.  Factors in the early failure of cryopreserved homograft pulmonary valves in children: preserved immunogenicity?

Authors:  R J Baskett; D B Ross; M A Nanton; D A Murphy
Journal:  J Thorac Cardiovasc Surg       Date:  1996-11       Impact factor: 5.209

7.  Midterm results with cryopreserved allograft valved conduits from the right ventricle to the pulmonary arteries.

Authors:  J A Hawkins; W W Bailey; T Dillon; D C Schwartz
Journal:  J Thorac Cardiovasc Surg       Date:  1992-10       Impact factor: 5.209

8.  Homograft conduit failure in infants is not due to somatic outgrowth.

Authors:  Winfield J Wells; Hector Arroyo; Ross M Bremner; John Wood; Vaughn A Starnes
Journal:  J Thorac Cardiovasc Surg       Date:  2002-07       Impact factor: 5.209

9.  Is the Ability index superior to the NYHA classification for assessing heart failure?: comparison of two classification scales in adolescents and adults with operated congenital heart defects.

Authors:  Kambiz Norozi; Armin Wessel; Reiner Buchhorn; Valentin Alpers; Jan O Arnhold; Monika Zoege; Siegfried Geyer
Journal:  Clin Res Cardiol       Date:  2007-06-27       Impact factor: 5.460

10.  Ten year experience with pulmonary allografts in children.

Authors:  D R Clarke; D A Bishop
Journal:  J Heart Valve Dis       Date:  1995-07
View more
  3 in total

1.  Time course of right ventricular functional parameters after surgical correction of tetralogy of Fallot determined by cardiac magnetic resonance.

Authors:  M Grothoff; J Hoffmann; L Lehmkuhl; H Abdul-Khaliq; S Nitzsche; A Mahler; I Dähnert; F Berger; M Gutberlet
Journal:  Clin Res Cardiol       Date:  2010-11-19       Impact factor: 5.460

2.  MRSA endocarditis of bovine Contegra valved conduit: a case report.

Authors:  Gani Bajraktari; Rozafa Olloni; Irfan Daullxhiu; Fadil Ademaj; Zana Vela; Mubekir Pajaziti
Journal:  Cases J       Date:  2009-01-15

3.  Pulmonary valve replacement after right ventricular outflow tract reconstruction with homograft vs Contegra®: a case control comparison of mortality and morbidity.

Authors:  Nicolas Poinot; Jean-Francois Fils; Hélène Demanet; Hugues Dessy; Dominique Biarent; Pierre Wauthy
Journal:  J Cardiothorac Surg       Date:  2018-01-17       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.